Exagen Analyst Ratings
Exagen Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 132.11% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 05/16/2023 | 132.11% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 03/22/2023 | 93.42% | BTIG | $6 → $5 | Maintains | Buy |
| 11/17/2022 | 170.79% | BTIG | $10 → $7 | Maintains | Buy |
| 11/15/2022 | 170.79% | Canaccord Genuity | $8 → $7 | Maintains | Buy |
| 05/13/2022 | 557.64% | Keybanc | $20 → $17 | Maintains | Overweight |
| 03/25/2022 | 673.69% | Keybanc | $30 → $20 | Maintains | Overweight |
| 11/11/2021 | 1060.54% | Keybanc | $33 → $30 | Maintains | Overweight |
| 04/15/2021 | 867.12% | Canaccord Genuity | → $25 | Initiates Coverage On | → Buy |
| 03/02/2021 | 1176.6% | KeyBanc | $32 → $33 | Maintains | Overweight |
| 11/10/2020 | 1137.91% | Keybanc | → $32 | Initiates Coverage On | → Overweight |
| 10/08/2020 | 596.32% | BTIG | → $18 | Initiates Coverage On | → Buy |
| 06/02/2020 | 673.69% | Cantor Fitzgerald | $19 → $20 | Assumes | → Overweight |
| 11/13/2019 | 867.12% | Cantor Fitzgerald | $18 → $25 | Maintains | Overweight |
| 10/14/2019 | 596.32% | Cantor Fitzgerald | → $18 | Initiates Coverage On | → Overweight |
| 10/14/2019 | 557.64% | Cowen & Co. | → $17 | Initiates Coverage On | → Outperform |
| 10/14/2019 | — | William Blair | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月22日 | 132.11% | 康托·菲茨杰拉德 | →$6 | 重申 | 超重→超重 |
| 2023年05月16日 | 132.11% | 康托·菲茨杰拉德 | →$6 | 重申 | 超重→超重 |
| 03/22/2023 | 93.42% | BTIG | $6→$5 | 维护 | 买 |
| 2022年11月17日 | 170.79% | BTIG | $10→$7 | 维护 | 买 |
| 2022年11月15日 | 170.79% | 卡纳科特·格纳奇 | $8→$7 | 维护 | 买 |
| 2022年05月13日 | 557.64% | KeyBanc | $20→$17 | 维护 | 超重 |
| 03/25/2022 | 673.69% | KeyBanc | $30→$20 | 维护 | 超重 |
| 2021年11月11日 | 1060.54% | KeyBanc | $33→$30 | 维护 | 超重 |
| 04/15/2021 | 867.12% | 卡纳科特·格纳奇 | →$25 | 开始承保 | →购买 |
| 03/02/2021 | 1176.6% | KeyBanc | $32→$33 | 维护 | 超重 |
| 11/10/2020 | 1137.91% | KeyBanc | →$32 | 开始承保 | →超重 |
| 10/08/2020 | 596.32% | BTIG | →$18 | 开始承保 | →购买 |
| 06/02/2020 | 673.69% | 康托·菲茨杰拉德 | $19→$20 | 假设 | →超重 |
| 2019年11月13日 | 867.12% | 康托·菲茨杰拉德 | $18→$25 | 维护 | 超重 |
| 2019年10月14日 | 596.32% | 康托·菲茨杰拉德 | →$18 | 开始承保 | →超重 |
| 2019年10月14日 | 557.64% | 考恩公司 | →$17 | 开始承保 | →跑赢大盘 |
| 2019年10月14日 | - | 威廉·布莱尔 | 开始承保 | →跑赢大盘 |
What is the target price for Exagen (XGN)?
埃克森美孚的目标价是多少？
The latest price target for Exagen (NASDAQ: XGN) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $6.00 expecting XGN to rise to within 12 months (a possible 132.11% upside). 5 analyst firms have reported ratings in the last year.
康托·菲茨杰拉德于2023年8月22日报道了埃克森(纳斯达克：XGN)的最新目标价。这家分析公司将目标价定为6美元，预计XGN将在12个月内上涨至(可能上涨132.11%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Exagen (XGN)?
分析师对埃克森美孚的最新评级是多少？
The latest analyst rating for Exagen (NASDAQ: XGN) was provided by Cantor Fitzgerald, and Exagen reiterated their overweight rating.
分析师对埃克森美孚(纳斯达克股票代码：XGN)的最新评级由康托·菲茨杰拉德提供，埃克森美孚重申其增持评级。
When is the next analyst rating going to be posted or updated for Exagen (XGN)?
Exagen(XGN)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exagen was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Exagen的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Exagen的上一次评级是在2023年8月22日提交的，所以你应该预计下一次评级将在2024年8月22日左右提供。
Is the Analyst Rating Exagen (XGN) correct?
分析师评级Exagen(XGN)正确吗？
While ratings are subjective and will change, the latest Exagen (XGN) rating was a reiterated with a price target of $0.00 to $6.00. The current price Exagen (XGN) is trading at is $2.59, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Exagen(XGN)评级被重申，目标价在0.00美元至6.00美元之间。埃克森美孚目前的交易价格为2.59美元，在分析师的预测范围内。